Procter & Gamble Health Recommends Final Dividend of ₹45/Share
Procter & Gamble Health Ltd announced its Board of Directors has recommended a final dividend of ₹45 per equity share for the financial year 2025-26. This dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM). The company also detailed the Tax Deducted at Source (TDS) implications for dividend income, outlining applicable rates for resident and non-resident shareholders. Resident shareholders with PAN will face a 10% TDS if their total dividend exceeds ₹10,000, while those without a valid PAN will be subject to 20% TDS. Specific exemptions and documentation requirements are provided for entities like LIC, GIC, Mutual Funds, and government bodies. Non-resident shareholders will be taxed at 20% or the Double Taxation Avoidance Agreement (DTAA) rate, whichever is lower.
Key Highlights
- Board recommends final dividend of ₹45 per equity share for FY25-26.
- Dividend payout is contingent on shareholder approval at the AGM.
- TDS implications detailed for resident and non-resident shareholders.
- PAN availability and tax status affect TDS rates for resident shareholders.
- Specific exemptions and documentation apply to institutional investors.
Price Impact
More from PGHL